One To Watch

ImmunityBio

A clinical-stage immunotherapy company developing innovative cancer vaccines and cell therapies targeting oncology and infectious diseases through immune system activation.

Company Overview

A clinical-stage immunotherapy company developing innovative cancer vaccines and cell therapies targeting oncology and infectious diseases through immune system activation. ImmunityBio focuses on creating therapies that target disease rather than suppressing immune systems. The company operates an extensive clinical program with 27 active trials across 13 different indications in both liquid and solid tumors. ImmunityBio has progressed 18 trials into Phase II or Phase III development stages.

Headquarters and Global Presence

ImmunityBio is headquartered in El Segundo, California, with additional operations in San Diego. The company employs 673 full-time staff and maintains a global presence through strategic partnerships. Recent expansion includes establishing an Irish subsidiary to support European commercialization efforts and partnerships in Saudi Arabia for Middle East market access.

Founding and History

Founded in 2014, ImmunityBio emerged as a developer of peptide-based vaccines for immunotherapy applications. The company has raised $169 million in funding since inception. ImmunityBio operates as a public company and has evolved from its early vaccine development focus into a comprehensive immunotherapy platform. The company previously operated under NantKwest before transitioning to its current structure.

Therapy Areas and Focus

ImmunityBio concentrates on oncology and infectious diseases, addressing serious unmet medical needs through immunotherapy approaches. The company's oncology focus spans both hematologic malignancies and solid tumors across 13 different cancer indications. In infectious diseases, the platform targets viral and bacterial pathogens through immune system enhancement. The therapeutic strategy emphasizes activating natural immune responses rather than traditional cytotoxic approaches.

Technology Platforms and Modalities

The company's technology platform centers on prophylactic vaccines, therapeutic vaccines, and recombinant vector vaccines. ImmunityBio's approach combines cancer vaccines with cell therapy products designed to stimulate targeted immune responses. The platform utilizes peptide-based vaccine technology alongside engineered cell therapies. This dual modality strategy aims to create durable immune memory while providing immediate therapeutic intervention.

Key Pipeline and Programs

ANKTIVA represents ImmunityBio's flagship approved immunotherapy, currently expanding access through European distribution partnerships with Accord Healthcare across 30 countries. The extensive clinical pipeline includes 27 active trials with 18 programs in Phase II or Phase III development. Key therapeutic areas include non-muscle invasive bladder cancer, where ANKTIVA has gained regulatory approval. Additional programs target various solid tumors and hematologic malignancies through the company's vaccine and cell therapy platforms.

Key Personnel

Richard Adcock serves as Chief Executive Officer, appointed in January 2021 after previously leading NantKwest. Adcock brings nearly 30 years of healthcare leadership experience and holds Six Sigma Master Black Belt certification. The management team includes Philip Scalzo as Chief Compliance Officer and Glenn Wright as Vice President of Market Access.

Strategic Partnerships

ImmunityBio has established a significant European distribution partnership with Accord Healthcare, deploying an 85-person sales force across 30 countries for ANKTIVA commercialization. The company secured strategic agreements in Saudi Arabia for regulatory approval, distribution, and potential manufacturing collaboration. These partnerships support ImmunityBio's mission to expand global access to its immunotherapy treatments while leveraging local market expertise.

FAQ Section

Successfully scaling ANKTIVA's commercial launch across global markets while advancing its extensive Phase II/III pipeline. The company must execute on multiple fronts simultaneously - commercial expansion, clinical development, and manufacturing capacity.

Immune activation therapies can provide durable responses by creating immunologic memory against cancer and infectious diseases. Unlike traditional chemotherapy or immunosuppressive approaches, this strategy harnesses the body's natural defense mechanisms for sustained therapeutic benefit.

The combination of therapeutic vaccines with cell therapy products creates a dual-modality platform addressing both immediate treatment needs and long-term immune protection. This integrated approach spans multiple disease areas using consistent immunologic principles.

ANKTIVA serves as ImmunityBio's first approved product and commercial validation of its immunotherapy platform. The drug's success in non-muscle invasive bladder cancer provides proof-of-concept for the broader pipeline and generates revenue to fund continued development.

Oncology dominates with 13 different cancer indications spanning both solid tumors and hematologic malignancies. Infectious diseases represent the secondary focus, targeting viral and bacterial pathogens through immune enhancement rather than traditional antimicrobial approaches.

ImmunityBio is in late-stage clinical development with commercial operations beginning through ANKTIVA's approval. The company operates 27 clinical trials with 18 programs in Phase II or Phase III, indicating significant near-term data catalysts.

Key catalysts and risks to monitor include:

• Phase II/III readouts across the 18 advanced-stage programs

• ANKTIVA commercial uptake in European markets through Accord partnership

• Regulatory submissions for additional ANKTIVA indications

• Manufacturing scale-up to support global commercialization demands

Want to Update your Company's Profile?